Lilly posts $24.4 billion in third-quarter revenue as guidance diverges among four companies
Key Facts
Eli Lilly posted revenue of $24.4 billion in the third quarter of 2026, up 39% year over year from $17.6 billion in the same period of 2025, beating analysts’ average estimate of $22.42 billion, according to Investing.com, citing company results. The report, published on October 29, said the stock rose more than 4% in premarket trading after the results and higher guidance. Chief Executive David Ricks said revenue growth came from “broad global demand” for Mounjaro and Zepbound. He added that the global launch of Foundayo and expanded U.S. coverage for obesity care helped drive growth. In its latest outlook, the company raised its 2026 revenue estimate to $91–92 billion, but lowered its adjusted earnings-per-share forecast to $35–36.
Bristol Myers Squibb’s quarterly results, by contrast, combined a beat on market estimates with a cut to its annual earnings forecast. Third-quarter earnings per share came in at $1.35, versus an estimate of $1.09, while revenue reached $13.07 billion, compared with consensus of $12.72 billion, according to Investing.com. The company raised its 2026 revenue outlook to a range of $49.75–50.25 billion, from a previous estimate of $49–50 billion, according to Reuters via AOL. But it lowered its adjusted earnings forecast to $6.35–6.55 per share, from $6.75–7.00. Reuters reported that the company recorded a charge of 60 cents per share during the quarter, while the stock rose 2.3% in premarket trading on October 29 after the results and guidance were announced.
At Oshkosh, Access segment data showed sales growth, while its chief executive pointed to delays in improving production flow. The segment’s sales rose 20.7%, or $229.9 million, to $1.34 billion in the third quarter of 2026, the company said. Oshkosh attributed the increase to higher volume in North America and improved pricing. Chief Executive John Pfeifer said “production flow improvements are taking longer than we previously expected.” He added that the company was taking steps to improve material flow and production scheduling, indicating that addressing production bottlenecks was still taking longer than planned.
In the industrial sector, Textron raised its annual earnings and industrial cash flow forecasts. The company set its 2026 adjusted earnings-per-share outlook at $6.55–6.65, according to results published via MarketScreener. It also raised its forecast for industrial cash flow before pension contributions to $800–900 million. These estimates reflect the company’s outlook for fiscal 2026. The figures alone do not establish the stock’s movement in any particular session, while the guidance focuses on what the company expects for earnings and cash flow over the rest of the year.